In brief
The episode argues that two big shifts are under way in medicine. The FDA's commissioner, Robert Califf, says drug regulation must adopt digital evidence, treat advisory committees as discussions rather than votes, and confront misinformation. STAT's Elaine Chen argues that powerful new weight loss drugs are recasting obesity as a treatable disease, while raising hard questions about safety, stigma, drug-company influence and cost.
The central tension is promise versus affordability. Obesity drugs and a new cholesterol pill look strikingly effective, yet the proof of long-term benefit is still pending. Even at lower prices, insurers could cover only a small share of eligible patients before budgets strain. Califf's regulatory reforms and Lilly's failed Alzheimer's trial show how evidence, not enthusiasm, is meant to decide what gets used and paid for.
Questions
Why did Lilly's Alzheimer's drug solanezumab fail, and does it hurt Lilly's other Alzheimer's drugs?
In the A4 study of people with amyloid plaque but no symptoms, solanezumab did not improve cognition or plaque measures. Damian Garde said it does not damage Lilly's core amyloid hypothesis, because it did not show plaque removal without clinical benefit.
What is the new Merck cholesterol pill and why does it matter?
It is an oral drug targeting PCSK9 that lowered LDL cholesterol about 60% at the highest dose in a phase two trial. The existing PCSK9 drugs are injections, so a pill could be more appealing, and Merck is expected to start phase three in the second half of 2023.
What does the FDA do about misinformation?
Robert Califf said the FDA tries to anticipate public reaction when it announces decisions and puts out fuller information up front. It also watches social media and responds quickly, including calling reporters, when it thinks something is wrong.
Why is the FDA looking at changing advisory committees?
Califf says their purpose is to gather expert thinking, not to take a vote, since the FDA makes the decisions. He also said the agency will review conflict-of-interest rules, which are a particular problem for rare diseases where most experts work on treatments.
Can the healthcare system afford GLP-1 weight loss drugs for everyone who qualifies?
Probably not, according to Elaine Chen. Almost half of US adults are eligible for Wegovy, and ICER estimated that even at a fair price of about $7,500 a year, covering less than 1% would start to pressure the system.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Eli Lilly and Company spent roughly a decade or more and over $1 billion trying to prove solanezumab could treat Alzheimer's disease, according to Damian Garde.
“So this is a medicine that Eli Lilly spent about a decade, maybe more, and in excess of $1 billion trying to prove could be a viable treatment for Alzheimer's disease.”
0:02:27 · Host · Solanezumab
The A4 study, run out of Harvard, enrolled people with detectable brain amyloid plaque who had no Alzheimer's symptoms.
“It enrolled patients who were likely to develop Alzheimer's disease based on having amyloid plaque in their brain detectably, but had not experienced any symptoms whatsoever.”
0:03:02 · Host · A4 study
The A4 study of solanezumab showed no benefit on cognitive function or on amyloid plaques.
“The study did not work at all, either in terms of measures of cognitive function or in terms of the amyloid plaques in question.”
0:03:02 · Host · A4 results · 2023
Eli Lilly's stock price fell after the solanezumab A4 result was reported, which Damian Garde found curious.
“And yet, Lilly's stock price went down, which I, you know, it's probably a fool's errand to try to unpack why stocks move”
0:03:33 · Host · Lilly stock · 2023
Damian Garde said Lilly's donanemab, an amyloid-targeting drug in phase three, would have looked less likely to succeed only if solanezumab had cleared plaque without clinical benefit.
“the other molecules, like Lily's denanumab, the one that is now in phase three, which also target amyloid, that they would have less likelihood of success”
0:04:18 · Host · Donanemab · 2023
In a phase two study, the highest dose of Merck's oral PCSK9-targeting drug reduced LDL cholesterol by about 60%.
“basically, the highest dose reduced patients' LDL or bad cholesterol by about 60 % with a pill.”
0:04:44 · Host · Oral PCSK9 drug · 2023
Merck was expected to start a phase three trial of its oral PCSK9 drug in the second half of 2023, according to Meg Terrell.
“Merck is expected to start that in the second half of 2023”
0:06:11 · Meg Terrell · Phase three · 2023
Amgen's injectable PCSK9 drug has passed $1 billion in annual sales, while Regeneron's has not, according to Meg Terrell.
“I mean, the Amgen drug has surpassed $1 billion in annual sales. The Regeneron one hasn't.”
0:06:11 · Meg Terrell · PCSK9 sales · 2023
Robert Califf marked one year as commissioner of the U.S. Food and Drug Administration around March 2023.
“Dr. Robert Califf recently marked his one-year anniversary as commissioner of the U.S. Food and Drug Administration.”
0:06:53 · Host · FDA commissioner · 2023
Robert Califf said the current system filters out about 85% of ineffective candidates in phase one, two and early phase three trials.
“We winnow out 85 % of things that don't work in phase one, two, and early phase three trials.”
0:14:13 · Robert Califf · Drug trials
Robert Califf said the US spends about $3.4 trillion on health care yet has a life expectancy five years shorter than other high-income countries.
“we're spending $3.4 1 trillion on health care with outcomes showing a five-year shorter life expectancy than other high-income countries”
0:14:48 · Robert Califf · US health spending
Robert Califf said FDA advisory committees exist to gather expert thinking rather than to take a vote, since the FDA makes the decisions.
“Purpose of the advisory committee is not to take a vote. Purpose of the advisory committee is to get the thinking of experts about the problem at hand.”
0:15:55 · Robert Califf · Advisory committees
Robert Califf said most COVID-19 deaths since vaccines became available were preventable with free vaccination, with or without an antiviral.
“most of the people dying of COVID since the vaccines were unnecessary deaths that could have been prevented with a free treatment, either vaccination alone or vaccination plus an antiviral.”
0:20:23 · Robert Califf · COVID-19 deaths
Robert Califf said US infant formula in-stock rates had returned to pre-recall levels, though some rural areas still lagged.
“First of all, our in-stock rates are back to where they were before the recall.”
0:22:16 · Robert Califf · Formula shortage · 2023
Robert Califf said the WIC program accounts for over half of US infant formula, giving the companies in it a dominant market position.
“The WIC program is responsible for over 50 % of the formula.”
0:23:31 · Robert Califf · WIC and formula
The company formerly known as Weight Watchers acquired a telehealth company to give its members access to prescription weight loss drugs.
“This week, the company formerly known as Weight Watchers made headlines when it acquired a telehealth company that will enable its members to access prescription weight loss drugs.”
0:25:14 · Host · WW acquisition · 2023
The GLP-1 drugs discussed include Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro.
“They are Novo Nordisk's Ozempic and Wagovi and Eli Lilly's Monjaro.”
0:25:23 · Meg Terrell · GLP-1 drugs · 2023
Elaine Chen reported that one doctor, funded by a Novo Nordisk grant, is tailoring and integrating obesity curricula with 10 medical schools.
“there's one doctor who, you know, through a grant from Novo is working to actually tailor and integrate the curricula with 10 medical schools.”
0:29:16 · Elaine Chen · Medical school curricula · 2023
Elaine Chen said side effects of the new obesity drugs so far appear manageable, mainly early nausea and diarrhea, with some concern about rare pancreatitis.
“So far, the side effects seem relatively okay. There's nausea, diarrhea at the beginning. There's concern about maybe potentially rare cases of pancreatitis.”
0:32:38 · Elaine Chen · Drug safety · 2023
Elaine Chen said there is concern that older people on these drugs could lose lean muscle mass too quickly and become frail.
“there's some concern that they could lose lean mass too quickly, which could lead to them becoming more frail”
0:32:38 · Elaine Chen · Lean mass · 2023
Data show reduced cardiovascular events in diabetes patients taking these drugs, but not yet in people with obesity alone, according to Elaine Chen.
“for patients with diabetes taking them, there is a reduced risk of cardiovascular events. But we don't yet have data on cardiovascular events for people just with obesity.”
0:34:34 · Elaine Chen · Cardiovascular outcomes · 2023
Damian Garde estimated more than 100 million people in the United States might be candidates for obesity drug therapy.
“there's in excess of 100 million people, I think, just in the United States who might be candidates for therapy.”
0:35:12 · Host · Eligible population · 2023